464 related articles for article (PubMed ID: 15983299)
1. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
2. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
[TBL] [Abstract][Full Text] [Related]
3. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
4. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Chiquette E; Ramirez G; Defronzo R
Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
[TBL] [Abstract][Full Text] [Related]
7. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
[TBL] [Abstract][Full Text] [Related]
8. Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Vergès B
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():15-8. PubMed ID: 18001314
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
[TBL] [Abstract][Full Text] [Related]
10. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
King AB; Armstrong DU
Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Patel J; Anderson RJ; Rappaport EB
Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
[TBL] [Abstract][Full Text] [Related]
12. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
LaCivita KA; Villarreal G
Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
[TBL] [Abstract][Full Text] [Related]
13. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
17. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Berhanu P; Kipnes MS; Khan MA; Perez AT; Kupfer SF; Spanheimer RC; Demissie S; Fleck PR
Diab Vasc Dis Res; 2006 May; 3(1):39-44. PubMed ID: 16784180
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
